Jubilant Therapeutics Inc. reports isoform-selective PAD4 inhibitors demonstrating high In Vitro selectivity and potency and In Vivo oral bioavailability and anti-tumor activity

PAD4 inhibition a novel pathway to inhibit tumor metastasis and tumor growth Data presented at the American Association of Cancer Research Annual Meeting 2022 BEDMINSTER, N.J., April 11, 2022 /PRNewswire/ — Jubilant Therapeutics Inc. a biopharmaceutical company advancing small molecule…

Leave a Reply

Your email address will not be published.